logo

For the Inventor, By the Inventor

Foster City, CA, United States of America

Gilead Calistoga LLC


USPTO Granted Patents = 16

% Expired Patents = 12.5



Forward Citations = 95

Loading Chart...
Loading Chart...

27 inventors (with patents filed for the assignee):

goldMedal Jerry B Evarts (12 out of 27 patents)

silverMedal Duong D Tran (7 out of 18 patents)

bronzeMedal Ernest A Carra (5 out of 20 patents)

4.  Fang Wang (5 out of 26 patents)

5.  Keiko Sujino (5 out of 16 patents)

6.  Roger G Ulrich (5 out of 12 patents)

7.  Neill A Giese (4 out of 11 patents)

8.  Brian Lannutti (3 out of 20 patents)

9.  Bing Shi (3 out of 41 patents)

10.  Stephane Perreault (3 out of 20 patents)

11.  Jennifer Anne Treiberg (3 out of 43 patents)

12.  Leena Patel (3 out of 23 patents)

13.  Michael J Gerber (3 out of 21 patents)

14.  W Michael Gallatin (3 out of 41 patents)

15.  Musong Kim (2 out of 25 patents)


16 patents:

1. 10730879 - Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one (2020-08-04),
2. 10442805 - Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one (2019-10-15),
3. 10154998 - Therapies for hematologic malignancies (2018-12-18),
4. 10059677 - Process for preparing phosphatidylinositol 3-kinase inhibitors and intermediates thereof (2018-08-28),
5. 10047060 - Process methods for phosphatidylinositol 3-kinase inhibitors (2018-08-14),
6. 9708327 - Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one (2017-07-18),
7. 9492449 - Therapies for hematologic malignancies (2016-11-15),
8. 9469643 - Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one (2016-10-18),
9. 9266878 - Phosphatidylinositol 3-kinase inhibitors (2016-02-23),
10. 9238070 - Therapies for hematologic malignancies (2016-01-19),
11. 9029384 - Phosphatidylinositol 3-kinase inhibitors (2015-05-12),
12. 9018221 - Phosphatidylinositol 3-kinase inhibitors (2015-04-28),
13. 8865730 - [object Object] (2014-10-21),
14. 8691829 - Treatment of liver disorders with PI3K inhibitors (2014-04-08),
15. 8546409 - Methods of treatment for solid tumors (2013-10-01),
Company Overview
Gilead Calistoga LLC, based in Foster City, California, is a biotechnology company focused on the development of innovative therapies for cancer and other serious diseases. The organization specializes in research and development of targeted treatments, particularly in the field of oncology, leveraging advanced scientific techniques to address unmet medical needs. Gilead Calistoga is committed to improving patient outcomes through its cutting-edge research and a strong emphasis on scientific excellence.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

16 Patents

#28 in Foster City, CA

#4,777 in California

#19,935 in US

#37,868 in the World

Foster City, CA (US)
Foster City, CA, United States of America

Gilead Calistoga LLC

Forward Citations = 95

27 inventors:

goldMedal Jerry B Evarts (12 out of 27 patents)

silverMedal Duong D Tran (7 out of 18 patents)

bronzeMedal Ernest A Carra (5 out of 20 patents)

4.  Fang Wang (5 out of 26 patents)

5.  Keiko Sujino (5 out of 16 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Gilead Calistoga LLC. Retrieved from https://idiyas.com/company/gilead-calistoga

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…